Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/84741
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration
Author: Feng, X.
Xiao, J.
Longville, B.
Tan, A.
Wu, X.
Cooper, M.
McAllister, I.
Isaacs, T.
Palmer, L.
Constable, I.
Citation: Ophthalmology, 2009; 116(10):1908-1912.e1
Publisher: Elsevier
Issue Date: 2009
ISSN: 0161-6420
1549-4713
Statement of
Responsibility: 
Xuefeng Feng, Jing Xiao, Brooke Longville, Alexander X.J. Tan, Xia Ni Wu, Matthew N. Cooper, Ian L. McAllister, Timothy Isaacs, Lyle J. Palmer, Ian J. Constable
Abstract: <h4>Purpose</h4>To investigate the association between complement factor H (CFH) and C-reactive protein (CRP) genotypes and response to photodynamic therapy (PDT) treatment for neovascular age-related macular degeneration (AMD).<h4>Design</h4>Retrospective cohort study.<h4>Participants</h4>The study cohort consisted of 273 neovascular AMD patients treated with PDT.<h4>Methods</h4>Genotypes were determined for the common T-->C single nucleotide polymorphism (SNP) in exon 9 of the CFH gene (rs1061170; Y402H), as well as 9 selected tagging SNPs across the CRP gene (rs2808635, rs1417938, rs1800947, rs1130864, rs1205, rs3093077, rs876538, rs876537, and rs1572970). Visual acuity outcome after PDT was retrospectively calculated and patients were classified as PDT-positive responders or PDT-negative responders. Logistic regression analysis was used to evaluate the association between individual SNPs and PDT treatment response while adjusting for relevant covariates.<h4>Main outcome measures</h4>Response to PDT treatment defined by visual acuity; genotypes of CFH Y402H and CRP polymorphism.<h4>Results</h4>Of the 273 patients, 75 had a positive response after PDT treatment. The frequency of CC genotype of the CFH Y402H polymorphism in the PDT-positive response group was lower than in the negative PDT response group (26.4% vs 31.6%) but this difference failed to reach statistical significance. Two CRP SNPs (rs2808635 and rs876538) were significantly associated with PDT treatment response. Positive treatment response was seen in individuals homozygous for the minor allele of the rs2808635 (GG; odds ratio [OR], 3.92; 95% confidence interval [CI], 1.40-10.97; P = 0.048) and rs876538 (AA; OR, 6.49; 95% CI, 1.65-25.47; P = 0.048) variants after adjusting for relevant covariates. The remaining 7 CRP genetic variants did not reveal any significant association with treatment response.<h4>Conclusions</h4>Our data did not show significant association between the CFH Y402H polymorphism and PDT treatment response for neovascular AMD; however, CRP genetic variants were associated with a positive response to PDT treatment for neovascular AMD.
Keywords: Humans
Macular Degeneration
Choroidal Neovascularization
Porphyrins
C-Reactive Protein
Complement Factor H
Photosensitizing Agents
Treatment Outcome
Photochemotherapy
Retrospective Studies
Visual Acuity
Genotype
Polymorphism, Single Nucleotide
Aged
Female
Male
Verteporfin
Rights: © 2009 by the American Academy of Ophthalmology
DOI: 10.1016/j.ophtha.2009.03.011
Published version: http://dx.doi.org/10.1016/j.ophtha.2009.03.011
Appears in Collections:Aurora harvest 2
Translational Health Science publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.